modelPatient_PKPG_1C_Gentamicin

Diagram of Patient_PKPG_1C_Gentamicin

Extends from Pharmacolibrary.Icons.BodyArtieralVenous, Pharmacolibrary.Icons.Pills.

Information

Pharmacogenomic (PGx) models seeks to quantify how inherited genetic variation modulates both drug pharmacokinetics and pharmacodynamics.

Example diagram mode of 1-compartment PK model of gentamicine modified by PGx influence on clearance rate. Clearance rate can be influenced by CYP2C19 genotype and SLC22A2 genotype. The
scale factors in the PGx modification of PK model is just an example estimation of influence on renal clearance. Correct values should be fit to specific published experimental results.

Simulation of PKPGx model of gentamicine with normal SLC22A2 alleles compared to allele
’808T’ with altered clearance.



Parameters

TypeNameDefaultDescription
StringSLC22A2_1"*1"
StringSLC22A2_2"*1"
StringCYP2C19_1"*1"
StringCYP2C19_2"*1"
Pharmacolibrary.Types.ClearanceCL1.6666666666666667e-6clearance
Pharmacolibrary.Types.VolumeVd0.0175volume of distribution
Pharmacolibrary.Types.MassConcentrationMIC0.002Minimal inhibitory concentration
Pharmacolibrary.Types.MassConcentrationC_tox_peak0.025Peak toxicity concentration
Pharmacolibrary.Types.MassConcentrationC_tox_valley0.0021Peak toxicity concentration

Components

TypeNameDefaultDescription
Pharmacolibrary.Sources.PeriodicDosedose
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentcentral
Pharmacolibrary.Pharmacokinetic.ClearanceDrivenEliminationelim
Pharmacolibrary.Sources.ClearanceConstelimClearance
Pharmacolibrary.Pharmacogenomics.Modifiers.ClearanceModifierComponentclearanceModifierComponent
Pharmacolibrary.Pharmacogenomics.PGx.GenotypePhenotypeComponentSLC22A2
Pharmacolibrary.Pharmacogenomics.PGx.GenotypePhenotypeComponentCYP2C19
Pharmacolibrary.Pharmacogenomics.Modifiers.ClearanceModifierComponentclearanceModifierComponent1